KPT-9274 is primarily investigated for its potential in cancer therapy. It functions as a dual inhibitor targeting PAK4 and NAMPT, two proteins involved in tumor cell survival and proliferation. By inhibiting PAK4, KPT-9274 disrupts signaling pathways that promote cancer cell growth and metastasis. Simultaneously, suppression of NAMPT interferes with cellular energy production, leading to cancer cell death. This dual mechanism makes KPT-9274 a candidate for treating solid tumors and hematologic malignancies. It has shown activity in preclinical models of cancers such as melanoma, leukemia, and renal cell carcinoma. Clinical trials are ongoing to evaluate its safety and efficacy in humans, particularly in patients with advanced cancers who have limited treatment options.